Synlogic Joins Russell 3000® Index

From Startup Synlogic Tx

Link to Full Article: https://investor.synlogictx.com/news-releases/news-release-details/synlogic-joins-russell-3000r-index

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 25, 2018–
Synlogic, Inc. (Nasdaq:
SYBX), a clinical stage company applying synthetic biology to
probiotics to develop novel, living medicines, today announced the
company’s addition to the Russell 3000®Index, following the
Russell US Indices’ annual reconstitution, effective Monday, June 25,
2018.

“We are pleased to benchmark Synlogic’s growth with our addition to the
Russell 3000 Index, which offers a platform to increase the company’s
visibility and exposure to leading institutional investors,” said Aoife
Brennan, M.B., B.Ch., Synlogic’s interim president and chief executive
officer and chief medical officer.

Membership in the Russell 3000® Index, which remains in place
for one year, means automatic inclusion in the large-cap Russell 1000®
Index or small-cap Russell 2000® Index as well as the
appropriate growth and value style indices. FTSE Russell determines
membership for its Russell US Indices primarily by objective,
market-capitalization rankings and style attributes. Russell US Indices
are widely used by investment managers and institutional investors as
the basis for index funds and as benchmarks for active investment
strategies. Approximately $9 trillion in assets are benchmarked against
Russell US Indices. Russell US Indices are part of FTSE Russell, a
leading global index provider.

For more information on the Russell 3000® Index and the
Russell US Indices’ reconstitution, go to the “Russell Reconstitution”
section on the FTSE
Russell website.

About Synlogic
Synlogic is pioneering the development of a novel class of living
medicines, Synthetic Biotic medicines, based on its proprietary drug
development platform. Synlogic leverages the tools and principles of
synthetic biology to genetically engineer probiotic microbes to perform
or deliver critical functions missing or damaged due to disease. The
company’s two lead programs, SYNB1020 and SYNB1618, target
hyperammonemia as a result of liver damage or genetic disease, and PKU,
respectively. When delivered orally, Synthetic Biotic medicines can act
from the gut to compensate for the dysfunctional metabolic pathway and
have a systemic effect, with the potential to significantly improve
symptoms of disease for affected patients. In addition, the company is
leveraging the broad potential of its platform to create Synthetic
Biotic medicines for the treatment of more common diseases, including
liver disease, inflammatory and immune disorders, and cancer. Synlogic
is collaborating with AbbVie to develop Synthetic Biotic-based
treatments for inflammatory bowel disease (IBD). For more information,
please visit www.synlogictx.com.

Forward-Looking Statements

This press release contains “forward-looking statements” that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, included in this
press release regarding strategy, future operations, future financial
position, future revenue, projected expenses, prospects, plans and
objectives of management are forward-looking statements. In addition,
when or if used in this press release, the words “may,” “could,”
“should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“plan,” “predict” and similar expressions and their variants, as they
relate to Synlogic may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to, statements
regarding the potential of Synlogic’s platform to develop therapeutics
to address a wide range of diseases including: inborn errors of
metabolism, liver disease, inflammatory and immune disorders, and
cancer; the future clinical development of Synthetic Biotic medicines;
the approach Synlogic is taking to discover and develop novel
therapeutics using synthetic biology; the potential of Synlogic’s
technology to treat hyperammonemia and phenylketonuria; and the expected
timing of Synlogic’s anticipated clinical trial initiations. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors, including: the
uncertainties inherent in the preclinical development process; the
ability of Synlogic to protect its intellectual property rights; and
legislative, regulatory, political and economic developments, as well as
those risks identified under the heading “Risk Factors” in Synlogic’s
filings with the SEC. The forward-looking statements contained in this
press release reflect Synlogic’s current views with respect to future
events. Synlogic anticipates that subsequent events and developments
will cause its views to change. However, while Synlogic may elect to
update these forward-looking statements in the future, Synlogic
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing Synlogic’s view as
of any date subsequent to the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180625005257/en/
Source: Synlogic, Inc.
MEDIA:SynlogicCourtney Heath, 617-872-2462courtney@scientpr.comorINVESTORS:SynlogicElizabeth
Wolffe, Ph.D., 617-207-5509liz@synlogictx.com

Please visit their site for more information: Synlogic Therapeutics.com

All,Biotechnology,Healthcare News
2018-06-27 04:33:37